European Respiratory Society International Congress 2025

IF 32.8 1区医学 Q1 CRITICAL CARE MEDICINE

Lancet Respiratory Medicine Pub Date : 2025-10-08 DOI:10.1016/s2213-2600(25)00366-2

Priya Venkatesan

{"title":"European Respiratory Society International Congress 2025","authors":"Priya Venkatesan","doi":"10.1016/s2213-2600(25)00366-2","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Early-life exposure to paracetamol versus ibuprofen</h2>Previous non-experimental studies suggest an association between paracetamol exposure in the first year of life and subsequent asthma and eczema developing in childhood; however, randomised trials are needed to establish whether a causal link truly exists. Stuart R Dalziel (University of Auckland, Auckland, New Zealand) presented 1-year results from the PIPPA Tamariki randomised <span><span>study</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> comparing the use of paracetamol versus ibuprofen in early life. The study included 3908 infants in New Zealand</section></section><section><section><h2>Astegolimab for COPD</h2>Triggers of exacerbations in chronic obstructive pulmonary disease (COPD) can release IL-33 that binds to the ST2 receptor and increase inflammation; therefore, targeting the IL-33/SL2 pathway is an area of therapeutic interest. Neil J Greening (University of Leicester, Leicester, UK) presented results from the phase 2b <span><span>ALIENTO trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> comparing astegolimab, a human IgG2 monoclonal antibody targeting ST2 and blocking IL-33 activity, versus placebo in current or former smokers aged 40–90 years</section></section><section><section><h2>Sotatercept for PAH</h2>Two studies were presented on sotatercept, a fusion protein that inhibits activin signalling, for the treatment of pulmonary arterial hypertension (PAH). In the first, Ioana R Preston (Tufts Medical Center, Boston, MA, USA) presented new safety data from the <span><span>SOTERIA</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> long-term follow-up study, the interim results for which were published <span><span>previously</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>. Chalmers commented “Sotatercept is a game changer in PAH supported by a series of impactful trials, [but] long-term safety of new therapies is</section></section><section><section><h2>Nerandomilast for IPF</h2>Justin M Oldham (University of Michigan, Ann Arbor, MI, USA) presented final data from the <span><span>FIBRONEER-IPF</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> phase 3 trial of the phosphodiesterase 4B inhibitor nerandomilast in patients with idiopathic pulmonary fibrosis (IPF). 1117 patients with a mean age of around 70 years were assigned to 12 weeks of nerandomilast 9 mg twice daily, nerandomilast 18 mg twice daily, or placebo. 77·7% of all patients were taking nintedanib or pirfenidone at enrolment. Previously <span><span>published</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> results from the trial</section></section><section><section><h2>Hypertonic saline and carbocisteine for bronchiectasis exacerbations</h2>Mucoactive drugs such as hypertonic saline and carbocisteine are commonly prescribed for patients with bronchiectasis to prevent exacerbations; however, there is little evidence for their effectiveness. Judy M Bradley (Wellcome–Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK) commented “Patients with bronchiectasis have often expressed frustration at taking medications that don't seem to make a difference.” Bradley presented results from the UK <span><span>CLEAR</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> trial</section></section>","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"33 1","pages":""},"PeriodicalIF":32.8000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(25)00366-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Early-life exposure to paracetamol versus ibuprofen

Previous non-experimental studies suggest an association between paracetamol exposure in the first year of life and subsequent asthma and eczema developing in childhood; however, randomised trials are needed to establish whether a causal link truly exists. Stuart R Dalziel (University of Auckland, Auckland, New Zealand) presented 1-year results from the PIPPA Tamariki randomised study comparing the use of paracetamol versus ibuprofen in early life. The study included 3908 infants in New Zealand

Astegolimab for COPD

Triggers of exacerbations in chronic obstructive pulmonary disease (COPD) can release IL-33 that binds to the ST2 receptor and increase inflammation; therefore, targeting the IL-33/SL2 pathway is an area of therapeutic interest. Neil J Greening (University of Leicester, Leicester, UK) presented results from the phase 2b ALIENTO trial comparing astegolimab, a human IgG2 monoclonal antibody targeting ST2 and blocking IL-33 activity, versus placebo in current or former smokers aged 40–90 years

Sotatercept for PAH

Two studies were presented on sotatercept, a fusion protein that inhibits activin signalling, for the treatment of pulmonary arterial hypertension (PAH). In the first, Ioana R Preston (Tufts Medical Center, Boston, MA, USA) presented new safety data from the SOTERIA long-term follow-up study, the interim results for which were published previously. Chalmers commented “Sotatercept is a game changer in PAH supported by a series of impactful trials, [but] long-term safety of new therapies is

Nerandomilast for IPF

Justin M Oldham (University of Michigan, Ann Arbor, MI, USA) presented final data from the FIBRONEER-IPF phase 3 trial of the phosphodiesterase 4B inhibitor nerandomilast in patients with idiopathic pulmonary fibrosis (IPF). 1117 patients with a mean age of around 70 years were assigned to 12 weeks of nerandomilast 9 mg twice daily, nerandomilast 18 mg twice daily, or placebo. 77·7% of all patients were taking nintedanib or pirfenidone at enrolment. Previously published results from the trial

Hypertonic saline and carbocisteine for bronchiectasis exacerbations

Mucoactive drugs such as hypertonic saline and carbocisteine are commonly prescribed for patients with bronchiectasis to prevent exacerbations; however, there is little evidence for their effectiveness. Judy M Bradley (Wellcome–Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK) commented “Patients with bronchiectasis have often expressed frustration at taking medications that don't seem to make a difference.” Bradley presented results from the UK CLEAR trial

查看原文本刊更多论文

2025年欧洲呼吸学会国际大会

早期接触扑热息痛与布洛芬之前的非实验研究表明，在生命的第一年接触扑热息痛与随后在儿童时期发生哮喘和湿疹之间存在关联；然而，需要随机试验来确定因果关系是否真的存在。Stuart R Dalziel（新西兰奥克兰大学）介绍了PIPPA Tamariki随机研究1年的结果，比较了早期使用扑热息痛和布洛芬的情况。该研究包括新西兰的3908名婴儿，阿司哥利单抗治疗COPD慢性阻塞性肺疾病（COPD）恶化的触发因素可以释放与ST2受体结合的IL-33并增加炎症；因此，靶向IL-33/SL2通路是一个治疗领域。Neil J Greening （University of Leicester, Leicester， UK）发表了2b期ALIENTO试验的结果，比较了阿斯特戈利单抗（一种靶向ST2并阻断IL-33活性的人IgG2单克隆抗体）与安慰剂在40-90岁当前或曾经吸烟者中的疗效。首先，Ioana R Preston （Tufts Medical Center, Boston， MA， USA）介绍了SOTERIA长期随访研究的新安全性数据，该研究的中期结果已在之前发表。Chalmers评论道：“Sotatercept是一系列有影响力的试验支持的PAH的游戏规则改变者，[但是]新疗法的长期安全性是nerandomilast治疗IPF。justin M Oldham（密歇根大学，Ann Arbor， MI， USA）提交了磷酸二酯酶4B抑制剂nerandomilast治疗特发性肺纤维化（IPF）患者的FIBRONEER-IPF 3期试验的最终数据。1117名平均年龄约为70岁的患者被分配到12周的nerandomilast 9 mg每日2次，nerandomilast 18 mg每日2次或安慰剂组。77.7%的患者在入组时正在服用尼达尼布或吡非尼酮。先前发表的试验结果：高渗盐水和卡西汀治疗支气管扩张加重粘液活性药物，如高渗盐水和卡西汀，通常用于支气管扩张患者，以防止加重；然而，几乎没有证据表明它们的有效性。朱迪·M·布拉德利（英国贝尔法斯特女王大学威尔康-沃尔夫森实验医学研究所）评论说：“支气管扩张患者经常对服用似乎没有效果的药物感到沮丧。”布拉德利介绍了英国CLEAR试验的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Respiratory Medicine RESPIRATORY SYSTEM-RESPIRATORY SYSTEM

CiteScore

87.10

自引率

0.70%

发文量

572

期刊介绍： The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject. The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.